Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360
android app
/
iOS App/ web portal.
{
"products": [
{
"_id": "665ef7cfea22b014e8aefff9",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "GLICLAGLAZE MR 30 ",
"description": "GLICLAGLAZE MR 30 \ngliclazide sr (30 mg)\nIntroduction\nGLICLAGLAZE MR 30 is specifically formulated for individuals managing Type 2 diabetes. This medication utilizes a sustained release (SR) form of Gliclazide at a 30 mg dosage, focusing on providing a steady, controlled release of the drug to maintain optimal blood sugar levels throughout the day.\n\nHow It Works\n\nGliclazide SR (30 mg): Gliclazide is a sulfonylurea class drug that increases insulin secretion from the pancreas. Unlike standard formulations, the SR version releases the medication gradually, which helps to stabilize blood sugar levels and reduces the risk of severe fluctuations that can lead to hypoglycemia. This mechanism not only enhances the body’s natural insulin use but also supports overall vascular health, decreasing the risk of complications associated with diabetes, such as cardiovascular disease.\nBenefits\nGLICLAGLAZE MR 30 is an excellent choice for patients who require a mild enhancement in their insulin secretion with a lower risk of hypoglycemia. The SR formulation provides a more predictable pharmacokinetic profile, which is crucial for maintaining a stable glycemic control. This can significantly improve the quality of life for patients by reducing common side effects associated with blood sugar spikes and drops.\n\nDosage and Administration\n\nDosage: The dose of GLICLAGLAZE MR 30 should be adjusted based on the patient’s blood glucose response and previous treatment history. Regular monitoring of blood glucose and glycated hemoglobin (HbA1c) levels is recommended to ensure that the dosage is effective.\nAdministration: This medication should be taken with breakfast or the first main meal of the day. The tablet should be swallowed whole to maintain the integrity of the sustained release mechanism.\nSide Effects\nPossible side effects of GLICLAGLAZE MR 30 include gastrointestinal issues such as nausea and upset stomach. Due to its sulfonylurea component, there is a risk of hypoglycemia, although it is generally lower compared to other sulfonylureas due to the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MR 30 is a practical and effective solution for managing Type 2 diabetes, especially suited for patients seeking a gentle modification in their diabetes treatment plan with sustained drug release. It simplifies diabetes management, potentially enhancing adherence and minimizing the risk of dosage-related complications. As with any medication, consultation with a healthcare provider is essential to tailor the treatment to individual needs and conditions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-mr-30-133422",
"price": 83.0,
"discountamount": 24.9,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"day",
"dose",
"life",
"body",
"drops",
"EMAIL",
"Order",
"upset",
"tablet",
"nausea",
"stomach",
"quality",
"SR) form",
"patients",
"Benefits",
"pancreas",
"adherence",
"integrity",
"breakfast",
"practical",
"lower risk",
"SR version",
"medication",
"conditions",
"Conclusion",
"individuals",
"information",
"sterisonline",
"Introduction",
"30 mg dosage",
"consultation",
"sterispharma",
"hypoglycemia",
"CALL/WHATSAPP",
"Gliclazide SR",
"HbA1c) levels",
"SR formulation",
"GLICLAGLAZE MR",
"first main meal",
"Type 2 diabetes",
"mild enhancement",
"individual needs",
"excellent choice",
"insulin secretion",
"effective solution",
"Regular monitoring",
"blood sugar spikes",
"healthcare provider",
"diabetes management",
"gentle modification",
"other sulfonylureas",
"common side effects",
"glycated hemoglobin",
"severe fluctuations",
"natural insulin use",
"Possible side effects",
"standard formulations",
"Administration Dosage",
"sulfonylurea component",
"sustained drug release",
"blood glucose response",
"cardiovascular disease",
"diabetes treatment plan",
"stable glycemic control",
"gastrointestinal issues",
"overall vascular health",
"sulfonylurea class drug",
"steady, controlled release",
"optimal blood sugar levels",
"previous treatment history",
"sustained release mechanism",
"dosage-related complications",
"sustained release formulation",
"predictable pharmacokinetic profile"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1291,
"imageuri": "https://productimages.withfloats.com/actual/665ef7d253245b8b6b459895.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665ef7d253245b8b6b459895.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:17:35.736Z",
"updatedon": "2024-06-04T11:17:35.736Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-mr-30-/1291",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE MR 30 ",
"category": "DIABETIC RANGE",
"tags": null,
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6661af452bed1f08484d625b",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "TRIGLICLAGLAZE 30 ",
"description": "TRIGLICLAGLAZE 30 \nGliclazide (SR) Pioglitazone and Metformin HCL (SR)\nTRIGLICLAGLAZE 30 is a combination medication formulated to manage type 2 diabetes mellitus effectively. It combines three key components: Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), each targeting different aspects of glucose regulation to achieve optimal blood sugar control.\n\nGliclazide (SR): Gliclazide is a sulfonylurea medication that works by stimulating the pancreas to release insulin, which helps lower blood sugar levels. The sustained-release (SR) formulation ensures a gradual and prolonged release of the medication, providing consistent glucose-lowering effects throughout the day.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of drugs and enhances insulin sensitivity in muscle and fat tissues. By improving the body's response to insulin, Pioglitazone helps reduce insulin resistance and promotes better glucose utilization by cells.\n\nMetformin HCI (SR): Metformin is a biguanide medication that works primarily by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects and providing extended blood sugar control.\n\nKey Benefits of TRIGLICLAGLAZE 30:\nComprehensive Glucose Control: The combination of Gliclazide (SR), Pioglitazone, and Metformin HCI (SR) targets multiple pathways involved in glucose metabolism. This comprehensive approach helps achieve better overall blood sugar control throughout the day.\n\nStimulates Insulin Release: Gliclazide stimulates insulin secretion from the pancreas, especially after meals, which is crucial for managing postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in muscle and fat tissues, allowing for better glucose uptake and utilization by cells. This action helps reduce insulin resistance, a hallmark of type 2 diabetes.\n\nReduces Hepatic Glucose Production: Metformin HCI (SR) reduces the production of glucose in the liver, helping to lower fasting blood sugar levels and prevent excessive glucose release into the bloodstream.\n\nExtended Blood Sugar Control: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, leading to consistent blood sugar control and minimizing the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) fluctuations.\n\nDosage and Administration:\nTRIGLICLAGLAZE 30 is typically taken orally once or twice daily, as prescribed by a healthcare provider.\nThe medication is often taken with meals to reduce the risk of gastrointestinal side effects.\nDosage adjustments may be necessary based on blood sugar levels and individual response to treatment. Follow your doctor's instructions carefully.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-30-134278",
"price": 125.0,
"discountamount": 37.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"day",
"body",
"risk",
"drugs",
"meals",
"Order",
"liver",
"cells",
"EMAIL",
"doctor",
"muscle",
"action",
"pancreas",
"hallmark",
"treatment",
"Gliclazide",
"fat tissues",
"information",
"medications",
"bloodstream",
"Pioglitazone",
"sterisonline",
"postprandial",
"hypoglycemia",
"fluctuations",
"instructions",
"sterispharma",
"Key Benefits",
"hyperglycemia",
"CALL/WHATSAPP",
"Metformin HCL",
"Metformin HCI",
"glucose uptake",
"Administration",
"TRIGLICLAGLAZE",
"low blood sugar",
"gradual release",
"Insulin Release",
"high blood sugar",
"prolonged release",
"insulin secretion",
"different aspects",
"multiple pathways",
"peripheral tissues",
"insulin resistance",
"Dosage adjustments",
"blood sugar levels",
"glucose metabolism",
"glucose regulation",
"glucose utilization",
"individual response",
"insulin sensitivity",
"healthcare provider",
"meal) glucose spikes",
"three key components",
"biguanide medication",
"combination medication",
"comprehensive approach",
"thiazolidinedione class",
"sulfonylurea medication",
"type 2 diabetes mellitus",
"excessive glucose release",
"Hepatic Glucose Production",
"overall blood sugar control",
"optimal blood sugar control",
"extended blood sugar control",
"gastrointestinal side effects",
"sustained-release formulation",
"Comprehensive Glucose Control",
"consistent blood sugar control",
"sustained-release (SR) formulation",
"consistent glucose-lowering effects"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1484,
"imageuri": "https://productimages.withfloats.com/actual/6661af49f21358d53af3ccec.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6661af49f21358d53af3ccec.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T12:44:53.071Z",
"updatedon": "2024-06-28T12:15:14.626Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/trigliclaglaze-30-/1484",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "TRIGLICLAGLAZE 30 ",
"category": "DIABETIC RANGE",
"tags": [
"TRIGLICLAGLAZE 30",
"Gliclazide (SR)",
"Pioglitazone",
"Metformin HCL (SR)",
"Metformin SR 500mg uses",
"Metformin hydrochloride 500 mg",
"Metformin SR 500 side effects"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "66615f8cccd5ce1a10758f47",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "PIOSTERIS 30 ",
"description": "PIOSTERIS 30 \nPioglitazone (30mg)\nIntroduction to PIOSTERIS 30\nPIOSTERIS 30 contains Pioglitazone 30mg, a medication used primarily for the management of type 2 diabetes mellitus. Pioglitazone belongs to a class of drugs known as thiazolidinediones (TZDs), which help improve blood sugar control by increasing the body's sensitivity to insulin. This medication is typically used in combination with diet and exercise to enhance glycemic control in adults with type 2 diabetes.\n\nWhat is Pioglitazone?\nOverview of Pioglitazone\nPioglitazone is an oral diabetes medicine that works by making cells more sensitive to insulin, thereby allowing the body to use insulin more effectively. This helps lower blood sugar levels in patients with type 2 diabetes. Pioglitazone can be used alone or in combination with other antidiabetic medications.\n\nMechanism of Action\nInsulin Sensitization: Pioglitazone works by activating peroxisome proliferator-activated receptor gamma (PPARγ) receptors, which are involved in the regulation of genes responsible for glucose and lipid metabolism. This activation increases the sensitivity of body tissues to insulin.\nGlucose Uptake: By improving insulin sensitivity, Pioglitazone enhances glucose uptake in muscle and adipose tissue and reduces hepatic glucose production, leading to lower blood sugar levels.\nBenefits of PIOSTERIS 30\nEffective Blood Sugar Management\nImproved Insulin Sensitivity: PIOSTERIS 30 helps improve the body's response to insulin, leading to better control of blood sugar levels.\nComprehensive Glycemic Control: By targeting insulin resistance, Pioglitazone provides a unique mechanism of action that complements other diabetes medications, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: PIOSTERIS 30 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, PIOSTERIS 30 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nLipid Profile Improvement: Pioglitazone has been shown to improve lipid profiles by lowering triglycerides and increasing HDL cholesterol levels, which can provide additional cardiovascular benefits.\nHow to Use PIOSTERIS 30\nDosage and Administration\nRecommended Dosage: The typical dosage of PIOSTERIS 30 is one tablet taken once daily. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with or without food. Swallow the tablet whole with a full glass of water. Consistency is key, so take the medication at the same time each day.\nGuidelines for Optimal Use\nConsistent Use: For best results, take PIOSTERIS 30 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/piosteris-30-134190",
"price": 95.0,
"discountamount": 28.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"TZDs",
"diet",
"food",
"cells",
"genes",
"water",
"Order",
"class",
"EMAIL",
"drugs",
"muscle",
"adults",
"Action",
"Support",
"readings",
"Overview",
"patients",
"same time",
"PIOSTERIS",
"full glass",
"Guidelines",
"neuropathy",
"one tablet",
"activation",
"regulation",
"Optimal Use",
"combination",
"information",
"Adjustments",
"Consistency",
"retinopathy",
"sterisonline",
"sterispharma",
"best results",
"Introduction",
"Reduced Risk",
"body tissues",
"CALL/WHATSAPP",
"triglycerides",
"Administration",
"typical dosage",
"lipid profiles",
"treatment plan",
"Consistent Use",
"Glucose Uptake",
"adipose tissue",
"Exercise Adjunct",
"PPARγ) receptors",
"unique mechanism",
"lipid metabolism",
"excellent adjunct",
"Pioglitazone 30mg",
"insulin resistance",
"thiazolidinediones",
"Recommended Dosage",
"insulin sensitivity",
"healthcare provider",
"Diabetes Management",
"individual response",
"blood sugar control",
"Insulin Sensitization",
"cardiovascular disease",
"HDL cholesterol levels",
"oral diabetes medicine",
"lifestyle modifications",
"long-term complications",
"type 2 diabetes mellitus",
"lower blood sugar levels",
"stable blood sugar levels",
"Lipid Profile Improvement",
"other diabetes medications",
"Additional Health Benefits",
"hepatic glucose production",
"Comprehensive Glycemic Control",
"other antidiabetic medications",
"Effective Blood Sugar Management",
"additional cardiovascular benefits",
"comprehensive blood sugar management",
"peroxisome proliferator-activated receptor gamma"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1407,
"imageuri": "https://productimages.withfloats.com/actual/66615f8f8e77bb2c715607af.png",
"tileimageuri": "https://productimages.withfloats.com/tile/66615f8f8e77bb2c715607af.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T07:04:44.526Z",
"updatedon": "2024-06-29T10:30:40.061Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//piosteris-30-/1407",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "PIOSTERIS 30 ",
"category": "DIABETIC RANGE",
"tags": [
"PIOSTERIS 30",
"Pioglitazone (30mg)",
"Pioglitazone 30mg uses",
"Pioglitazone 30mg side effects",
"Pioglitazone dose",
"pioglitazone price"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6661614c870e7b20c49e4e49",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "PIOSTERIS 7.5 ",
"description": "PIOSTERIS 7.5 \nPioglitazone (7.5mg)\nIntroduction to PIOSTERIS 7.5\nPIOSTERIS 7.5 contains Pioglitazone 7.5mg, a medication used primarily for the management of type 2 diabetes mellitus. Pioglitazone belongs to a class of drugs known as thiazolidinediones (TZDs), which help improve blood sugar control by increasing the body's sensitivity to insulin. This medication is typically used in combination with diet and exercise to enhance glycemic control in adults with type 2 diabetes.\n\nWhat is Pioglitazone?\nOverview of Pioglitazone\nPioglitazone is an oral diabetes medication that works by making cells more sensitive to insulin, thereby allowing the body to use insulin more effectively. This helps lower blood sugar levels in patients with type 2 diabetes. Pioglitazone can be used alone or in combination with other antidiabetic medications.\n\nMechanism of Action\nInsulin Sensitization: Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPARγ) receptors, which are involved in the regulation of genes responsible for glucose and lipid metabolism. This activation increases the sensitivity of body tissues to insulin.\nGlucose Uptake: By improving insulin sensitivity, Pioglitazone enhances glucose uptake in muscle and adipose tissue and reduces hepatic glucose production, leading to lower blood sugar levels.\nBenefits of PIOSTERIS 7.5\nEffective Blood Sugar Management\nImproved Insulin Sensitivity: PIOSTERIS 7.5 helps improve the body's response to insulin, leading to better control of blood sugar levels.\nComprehensive Glycemic Control: By targeting insulin resistance, Pioglitazone provides a unique mechanism of action that complements other diabetes medications, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: PIOSTERIS 7.5 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, PIOSTERIS 7.5 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nLipid Profile Improvement: Pioglitazone has been shown to improve lipid profiles by lowering triglycerides and increasing HDL cholesterol levels, which can provide additional cardiovascular benefits.\nHow to Use PIOSTERIS 7.5\nDosage and Administration\nRecommended Dosage: The typical dosage of PIOSTERIS 7.5 is one tablet taken once daily. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with or without food. Swallow the tablet whole with a full glass of water. Consistency is key, so take the medication at the same time each day.\nGuidelines for Optimal Use\nConsistent Use: For best results, take PIOSTERIS 7.5 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/piosteris-7-5-133430",
"price": 59.0,
"discountamount": 17.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"food",
"TZDs",
"diet",
"lower",
"cells",
"class",
"water",
"drugs",
"EMAIL",
"Order",
"genes",
"adults",
"muscle",
"Action",
"Support",
"readings",
"Overview",
"patients",
"same time",
"PIOSTERIS",
"one tablet",
"full glass",
"regulation",
"activation",
"neuropathy",
"Guidelines",
"retinopathy",
"combination",
"Consistency",
"Adjustments",
"information",
"Optimal Use",
"best results",
"Reduced Risk",
"sterispharma",
"body tissues",
"Pioglitazone",
"Introduction",
"sterisonline",
"triglycerides",
"CALL/WHATSAPP",
"typical dosage",
"Administration",
"treatment plan",
"Consistent Use",
"lipid profiles",
"adipose tissue",
"Glucose Uptake",
"Exercise Adjunct",
"lipid metabolism",
"unique mechanism",
"PPARγ) receptors",
"excellent adjunct",
"insulin resistance",
"thiazolidinediones",
"Recommended Dosage",
"insulin sensitivity",
"Diabetes Management",
"blood sugar control",
"healthcare provider",
"individual response",
"Insulin Sensitization",
"cardiovascular disease",
"HDL cholesterol levels",
"long-term complications",
"lifestyle modifications",
"oral diabetes medication",
"type 2 diabetes mellitus",
"Lipid Profile Improvement",
"stable blood sugar levels",
"other diabetes medications",
"Additional Health Benefits",
"hepatic glucose production",
"Comprehensive Glycemic Control",
"other antidiabetic medications",
"Effective Blood Sugar Management",
"additional cardiovascular benefits",
"comprehensive blood sugar management",
"peroxisome proliferator-activated receptor gamma"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1410,
"imageuri": "https://productimages.withfloats.com/actual/6661614f7b1fc3f9dd4c82f7.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6661614f7b1fc3f9dd4c82f7.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-06T07:12:12.153Z",
"updatedon": "2024-06-29T10:23:25.301Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/piosteris-7-5-/1410",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "PIOSTERIS 7.5 ",
"category": "DIABETIC RANGE",
"tags": [
"PIOSTERIS 7.5",
"Pioglitazone (7.5mg)",
"pioz 7.5 price",
"pioz 7.5 side effects",
"tab pioz 7.5 uses",
"pioz 7.5 tablet 10"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "666050a6ea22b014e8af196f",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "LINALIGLIP M 5/500 ",
"description": "LINALIGLIP M 5/500 \nLinagliptin 5mg and Metformin Hydrochloride (SR) 500mg\nIntroduction to LINALIGLIP M 5/500\nLINALIGLIP M 5/500 is a combination medication that includes Linagliptin 5mg and Metformin Hydrochloride (Sustained Release) 500mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Linagliptin and Metformin, LINALIGLIP M 5/500 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Linagliptin and Metformin?\nOverview of Linagliptin\nLinagliptin is a DPP-4 (dipeptidyl peptidase-4) inhibitor that helps regulate blood glucose levels by increasing insulin release and decreasing glucagon levels in response to meals. By enhancing incretin hormones, Linagliptin aids in maintaining better overall blood sugar control throughout the day.\n\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release (SR) formulation ensures a prolonged effect throughout the day.\n\nBenefits of LINALIGLIP M 5/500\nEffective Blood Sugar Management\nPostprandial and Fasting Glucose Control: Linagliptin helps regulate postprandial (after-meal) glucose levels, while Metformin assists in lowering fasting glucose levels by promoting insulin sensitivity and reducing hepatic glucose production.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets multiple pathways of glucose regulation, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: LINALIGLIP M 5/500 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, LINALIGLIP M 5/500 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is known to have a neutral or weight-reducing effect, making it beneficial for patients concerned about weight gain.\nCardiovascular Protection: The combination may offer additional cardiovascular benefits by improving overall metabolic health.\nConvenience and Compliance\nTwice-Daily Dosing: The sustained-release formulation of Metformin allows for effective blood sugar control with twice-daily dosing, improving patient compliance and convenience.\nReduced Pill Burden: Combining two effective diabetes medications into one pill simplifies the treatment regimen, making it easier for patients to adhere to their prescribed therapy.\nHow to Use LINALIGLIP M 5/500\nDosage and Administration\nRecommended Dosage: The typical dosage of LINALIGLIP M 5/500 is one tablet taken twice daily, with meals. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take LINALIGLIP M 5/500 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/linaliglip-m-5-500-134301",
"price": 245.0,
"discountamount": 73.5,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"day",
"body",
"Diet",
"Order",
"EMAIL",
"liver",
"meals",
"water",
"amount",
"action",
"neutral",
"Support",
"Overview",
"patients",
"one pill",
"readings",
"biguanide",
"Guidelines",
"full glass",
"one tablet",
"neuropathy",
"Optimal Use",
"utilization",
"retinopathy",
"Convenience",
"Adjustments",
"information",
"weight gain",
"Introduction",
"Reduced Risk",
"best results",
"sterispharma",
"Postprandial",
"sterisonline",
"CALL/WHATSAPP",
"effectiveness",
"typical dosage",
"dual mechanism",
"Administration",
"treatment plan",
"Consistent Use",
"insulin release",
"Linagliptin 5mg",
"glucagon levels",
"two medications",
"prolonged effect",
"Exercise Adjunct",
"incretin hormones",
"Weight Management",
"Sustained Release",
"treatment regimen",
"excellent adjunct",
"multiple pathways",
"LINALIGLIP M 5/500",
"glucose regulation",
"patient compliance",
"Twice-Daily Dosing",
"Recommended Dosage",
"prescribed therapy",
"individual response",
"insulin sensitivity",
"Reduced Pill Burden",
"Diabetes Management",
"healthcare provider",
"meal) glucose levels",
"blood glucose levels",
"cardiovascular disease",
"combination medication",
"weight-reducing effect",
"Fasting Glucose Control",
"lifestyle modifications",
"Metformin Hydrochloride",
"long-term complications",
"complementary mechanisms",
"type 2 diabetes mellitus",
"overall metabolic health",
"Cardiovascular Protection",
"peripheral glucose uptake",
"stable blood sugar levels",
"Additional Health Benefits",
"hepatic glucose production",
"overall blood sugar control",
"gastrointestinal discomfort",
"sustained-release formulation",
"effective blood sugar control",
"comprehensive glycemic control",
"Effective Blood Sugar Management",
"dipeptidyl peptidase-4) inhibitor",
"additional cardiovascular benefits",
"sustained-release (SR) formulation",
"two effective diabetes medications",
"comprehensive blood sugar management"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1384,
"imageuri": "https://productimages.withfloats.com/actual/666050a84f159c14e162c5d7.png",
"tileimageuri": "https://productimages.withfloats.com/tile/666050a84f159c14e162c5d7.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-05T11:48:54.497Z",
"updatedon": "2024-06-29T11:16:30.61Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/linaliglip-m-5-500-/1384",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "LINALIGLIP M 5/500 ",
"category": "DIABETIC RANGE",
"tags": [
"LINALIGLIP M 5/500",
"Linagliptin 5mg",
"Metformin Hydrochloride (SR) 500mg",
"Metformin hydrochloride SR 500 mg uses",
"Metformin SR 500 side effects",
"Metformin SR 500 dosage"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "665ef6a3161afa2274ff2581",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "GLICLAGLAZE MET ",
"description": "GLICLAGLAZE MET \ngliclazide SR (60mg),Metformin SR (500 mg)\nIntroduction\nGLICLAGLAZE MET is an advanced formulation designed for the effective management of Type 2 diabetes. This oral medication combines sustained release (SR) forms of Gliclazide (60 mg) and Metformin (500 mg), offering controlled and consistent blood glucose control throughout the day.\n\nMechanism of Action\n\nGliclazide SR (60 mg): As a sulfonylurea drug, Gliclazide SR works by stimulating insulin secretion from the beta cells of the pancreas. The sustained release form provides a gradual increase in insulin levels, reducing the risk of sudden drops in blood sugar that can lead to hypoglycemia.\nMetformin SR (500 mg): Metformin SR decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues, notably muscles. Its sustained release formulation ensures a steady effect on blood sugar levels, improving metabolic response without the peaks and troughs associated with immediate-release forms.\nBenefits\nGLICLAGLAZE MET is specifically tailored to provide a more stable and prolonged effect in controlling blood sugar, which can enhance patient compliance and comfort. The combination of Gliclazide SR and Metformin SR in one tablet simplifies the treatment regimen, potentially improving adherence and reducing the risk of missed doses.\n\nDosage and Administration\n\nDosage: The dosage of GLICLAGLAZE MET should be individualized based on the patient's current control and therapeutic response. It is crucial to monitor blood glucose regularly to adjust the dosage appropriately.\nAdministration: This medication should be taken with meals to minimize gastrointestinal side effects and improve the absorption of the drug.\nSide Effects\nWhile GLICLAGLAZE MET is generally well tolerated, some patients may experience side effects such as gastrointestinal discomfort, including nausea and diarrhea. The risk of hypoglycemia is present but is generally lower with the sustained release formulation.\n\nConclusion\nGLICLAGLAZE MET offers a balanced and effective approach to managing Type 2 diabetes by combining two proven diabetes medications in a sustained release form. This regimen not only aids in maintaining steady blood glucose levels but also supports overall diabetes management by enhancing patient adherence to treatment. Patients are encouraged to maintain a dialogue with their healthcare provider to optimize treatment outcomes and address any concerns during their treatment journey.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/gliclaglaze-met-133421\n\n\n\n\n\n",
"price": 149.0,
"discountamount": 44.7,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"mg",
"day",
"risk",
"Order",
"EMAIL",
"peaks",
"doses",
"meals",
"stable",
"Action",
"nausea",
"muscles",
"troughs",
"Benefits",
"pancreas",
"diarrhea",
"balanced",
"dialogue",
"concerns",
"patients",
"SR) forms",
"Mechanism",
"beta cells",
"Conclusion",
"one tablet",
"controlled",
"absorption",
"combination",
"information",
"Metformin SR",
"sudden drops",
"hypoglycemia",
"Introduction",
"sterispharma",
"sterisonline",
"steady effect",
"CALL/WHATSAPP",
"gliclazide SR",
"insulin levels",
"oral medication",
"current control",
"Type 2 diabetes",
"GLICLAGLAZE MET",
"gradual increase",
"prolonged effect",
"insulin secretion",
"patient adherence",
"treatment journey",
"treatment regimen",
"sulfonylurea drug",
"effective approach",
"blood sugar levels",
"metabolic response",
"peripheral tissues",
"patient compliance",
"treatment outcomes",
"healthcare provider",
"insulin sensitivity",
"advanced formulation",
"effective management",
"therapeutic response",
"Administration Dosage",
"sustained release form",
"immediate-release forms",
"hepatic glucose production",
"overall diabetes management",
"steady blood glucose levels",
"gastrointestinal discomfort",
"gastrointestinal side effects",
"two proven diabetes medications",
"consistent blood glucose control"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1289,
"imageuri": "https://productimages.withfloats.com/actual/665ef6a67b1fc3f9dd48259d.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665ef6a67b1fc3f9dd48259d.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-06-04T11:12:35.652Z",
"updatedon": "2024-06-04T11:12:35.652Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM//gliclaglaze-met-/1289",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "GLICLAGLAZE MET ",
"category": "DIABETIC RANGE",
"tags": null,
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "665475a201264c1c309ca9a4",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "DILTITAB 30 15's Blister ",
"description": "DILTITAB 30 15's Blister \nDiltiazem HCL (SR)\nDiltitab 30, featuring Diltiazem HCL SR, is formulated to manage hypertension and chronic stable angina effectively.\nUses:\nIt reduces high blood pressure and alleviates chest pain associated with angina.\nDiltiazem's sustained release ensures prolonged effect and stable blood levels.",
"price": 44.0,
"discountamount": 14.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 7,
"_keywords": [
"Uses",
"Blister",
"DILTITAB",
"chest pain",
"hypertension",
"Diltiazem HCL SR",
"prolonged effect",
"sustained release",
"high blood pressure",
"stable blood levels",
"chronic stable angina"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 1190,
"imageuri": "https://productimages.withfloats.com/actual/665475c324482c9eb9c4782a.png",
"tileimageuri": "https://productimages.withfloats.com/tile/665475c324482c9eb9c4782a.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2024-05-27T11:59:30.525Z",
"updatedon": "2024-05-27T11:59:30.525Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/Blister/1190",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "Diltiazem HCL (SR)",
"category": "CARDIOLOGYRANGE",
"tags": null,
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": "",
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6842b8014256f7114dfbd884",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "TRELAQWK 100",
"description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.",
"price": 3.0,
"discountamount": 1.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": [
"medical advice",
"generally safe",
"healthcare provider",
"food preferably",
"extended halflife",
"crucial role",
"dpp4 enzyme",
"sulfonylureas mechanism",
"antidiabetic medications",
"low risk",
"vital role",
"sustainable option",
"regular exercise",
"healthy diet",
"effective approach",
"support adults",
"trelaqwk 100trelaqwk 100",
"hormones play",
"natural hormones",
"dose seek guidance",
"promote insulin release",
"degrades incretin hormones",
"experience unusual symptoms",
"skin irritation seek",
"onceaweek administration setting",
"improved glycemic control",
"regulating blood sugar",
"weight gain carries",
"suppress glucagon playing",
"improving glycemic control"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2132,
"imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-06-06T09:42:25.371Z",
"updatedon": "2025-06-11T11:17:09.096Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "Trelagliptin 100mg",
"category": "DIABETIC RANGE",
"tags": [
"Trelagliptin side effects",
"Trelagliptin brand name",
"Trelagliptin brands in India",
"Trelagliptin uses",
"Trelagliptin 100mg"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
},
{
"_id": "6825c6cc966e2a18bb4b35a6",
"fptag": "STERISHEALTHCARE",
"merchantname": null,
"customwidgets": null,
"externalsourceid": null,
"name": "GLIDAPA PIO",
"description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.",
"price": 255.0,
"discountamount": 77.0,
"currencycode": "INR",
"priority": 1000000,
"isfreeshipmentavailable": false,
"shipmentduration": 1,
"_keywords": [
"medication inform",
"pioglitazone risk",
"regular exercise",
"balanced diet",
"doctor maintain",
"glucose uptake",
"notice symptoms",
"antidiabetic drugs",
"swelling caused",
"advised alongside",
"skip doses",
"healthcare provider",
"effectively directions",
"synergistic effect",
"glycemic control",
"cardiovascular problems",
"complementary mechanisms",
"fat muscle",
"diabetesrelated complications",
"insulin resistance",
"bodys sensitivity",
"glidapa pio",
"urine pioglitazone 15mg",
"taking glidapa pio",
"bladder cancer risk",
"improve insulin sensitivity",
"improves insulin sensitivity",
"glidapa pioglidapa pio",
"dapagliflozin weight gain",
"increased urination due",
"urinary tract infections",
"experience side effects",
"insulinresponsive tissues enhancing",
"liver cells facilitating"
],
"isarchived": false,
"isavailable": true,
"applicationid": null,
"productindex": 2114,
"imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png",
"tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png",
"images": null,
"totalqueries": 0,
"gpid": null,
"groupproductid": null,
"createdon": "2025-05-15T10:49:48.361Z",
"updatedon": "2025-05-15T10:50:30.602Z",
"buyonlinelink": null,
"producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114",
"availableunits": -1.0,
"iscodavailable": false,
"isprepaidonlineavailable": false,
"maxcodorders": 0,
"maxprepaidonlineorders": 0,
"uniquepaymenturl": null,
"brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets",
"category": "DIABETIC RANGE",
"tags": [
"Dapagliflozin, pioglitazone combination",
"Dapagliflozin, pioglitazone combination",
"Dapagliflozin Pioglitazone CDSCO"
],
"variants": false,
"keyspecification": null,
"otherspecifications": null,
"pickupaddressreferenceid": null,
"paymenttype": "UniquePaymentUrl",
"producttype": "products",
"hsncode": null,
"gstslab": 0.0,
"isnotforsale": false
}
],
"hasmoreitems": false,
"isapirequest": false,
"totalresults": 27,
"query": null,
"floatingpoint": null
}